|This Slide: #56 of 100|
Slide #56. The Medicines Company — Rempex Pharmaceuticals, Inc.
The Medicines Company (MDCO)
Rempex Pharmaceuticals, Inc.
The Medicines Company announced that it has acquired Rempex Pharmaceuticals, Inc., a company with multiple potential new therapies focused on multi-drug resistant gram-negative bacteria. The Medicines Company paid Rempex equity holders $140 million in an upfront payment at the closing of the deal. In addition, The Medicines Company has agreed to pay Rempex equity holders milestone payments subsequent to the closing, including certain development and regulatory approval milestones totaling $214 million, and commercial milestones totaling $120 million. The Medicines Company has acquired several anti-infective assets as a result of the transaction: Carbavance, Minocin IV, RPX-602, and a preclinical developmental program of novel investigational agents.
Medicines is a biopharmaceutical company. Co. is focused on inclisiran, the investigational RNA interference therapeutic, that inhibits production of proprotein convertase subtilisin/kexin type 9, a main protein that controls low-density lipoprotein-cholesterol levels. Co. has the right to develop, manufacture and commercialize inclisiran under its collaboration agreement with Alnylam Pharmaceuticals, Inc.
Open the MDCO Page at The Online Investor »
Free MDCO Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Hold (2.44 out of 4)
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite